Expression of P-glycoprotein in human retinoblastoma and its clinical significance

[1]  H. Rotheneder,et al.  Regulation of the MDR1 promoter by E2F1 and EAPP , 2013, FEBS letters.

[2]  J. Toscano-Garibay,et al.  Regulation exerted by miRNAs in the promoter and UTR sequences: MDR1/P-gp expression as a particular case. , 2012, DNA and cell biology.

[3]  T. Kivelä.  The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death , 2009, British Journal of Ophthalmology.

[4]  R. Ren,et al.  [Studies on multidrug resistance associated protein in retinoblastoma]. , 2009, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.

[5]  A. Odashiro,et al.  Histopathological features and P-glycoprotein expression in retinoblastoma. , 2005, Investigative ophthalmology & visual science.

[6]  M. Burnier,et al.  Relationship between histopathological features of chemotherapy treated retinoblastoma and P‐glycoprotein expression , 2005, Clinical & experimental ophthalmology.

[7]  M. Shanmugam,et al.  Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma , 2004, British Journal of Ophthalmology.

[8]  W. Deegan.  Emerging strategies for the treatment of retinoblastoma , 2003, Current opinion in ophthalmology.

[9]  H. Coley,et al.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[10]  J. Robert,et al.  Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. , 1998, Cytometry.

[11]  T. Grogan,et al.  Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. , 1997, Cancer research.

[12]  C. Shields,et al.  Chemoreduction in the initial management of intraocular retinoblastoma. , 1996, Archives of ophthalmology.

[13]  M. Clynes,et al.  Multidrug resistance in ocular melanoma. , 1996, The British journal of ophthalmology.

[14]  J. O'Brien,et al.  Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  C. Duhem,et al.  What Does Multidrug Resistance (MDR) Expression Mean in the Clinic? , 1996, The oncologist.

[16]  B. Sikic,et al.  Drug resistance in clinical oncology and hematology. Introduction. , 1995, Hematology/Oncology Clinics of North America.

[17]  V. Ling,et al.  P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. , 1991, The New England journal of medicine.

[18]  B. Gallie,et al.  Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. , 1991, Ophthalmology.

[19]  V. Ling,et al.  Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Gallie,et al.  Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. , 1989, Anticancer research.

[21]  C. Shields,et al.  Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.